Skip to content

The Big Deals 💣 : Electra, Scalinx, Enyo Pharma, Nabla & more

Electra lights a fuse on the new year with a €304m round to build out its EV charting stations.

Electra founders: Julien Belliato, Aurélien de Meaux, Augustin Derville ©DR.
Electra founders: Julien Belliato, Aurélien de Meaux, Augustin Derville ©DR.

🔥 The Mega deal: Electra

What: A Paris-based manufacturer of fast-charging EV stations.

Why: To remove all barriers to the adoption of electric cars by deploying the most efficient network of fast-charging stations in Europe and making charging EVs as easy as filling up the petrol tank.

Funding: €304 million

Who: Co-founders, Aurélien de Meaux (CEO), Augustin Derville (CDO), Julien Belliato (COO)

Investors: PGGM (Dutch pension fund), Bpifrance, Eurazeo Infrastructure, Serena, Rive Private Investment, 574 Invest (investment branch of the national rail company, SNCF).

What's next: This staggering Series B round will go to consolidating Electra's position by deploying 2,200 stations across the 8 European countries in which they are present— representing 15k charging points — by 2030.

What: Scalinx, a manufacturer of signal conversion and processing chips for antennas.

Why: To enable analog-to-digital and digital-to-analog conversion of wide-band signals with low power consumption for wired and wireless communications, test and measurement equipment, and radars

Funding: €34 million

Who: Founder & CEO, Hussein Fakhoury

Investors: Thales, Go Capital, Bpifrance, WaterStart Capital, Normandie Participations, BNP Paribas Développement, Unexo

What's next: This new round of funding will enable the company to develop cutting-edge system-on-chip (SoC) solutions and expand its customer base.

What: Vulkam, a Deeptech company that develops amorphous metals (metallic glasses) known as "Vulkalloys®".

Why: To create unparalleled micro-mechanical parts, for use in industrial and medical equipment.

Funding: €34 million (of which €14 m equity)
Who: Founder & President, Sébastien Gravier

Investors: SEB industrial group & Bpifrance
What's Next: Vulkam will use the fresh funds to finance the 2025 operational launch of its first factory located in Isère and dedicated to the production of its new metals.

What: Enyo Pharma is a biotech specializing in producing trial medicines for rare kidney diseases.

Why: To enhance the quality of life and prevent end-stage renal failure and dialysis in patients with kidney diseases.

Funding: €27 million
Who: Co-founders Jacky Vonderscher , Laurène Meyniel-Schicklin, Dr Benoît de Chassey, Pr Patrice André, Dr Vincent Lotteau, Dr Jean-Jacques Garaud

Investors: OrbiMed, Morningside Ventures, AndEra Partners, Bpifrance InnoBio, & Bpifrance Large Ventures
What's Next: The raise will finance a new clinical study of their trial medicine, "Vonafexor", to be tested on Alport syndrome patients during the first half of this year and continue investments in the R&D of Vonafexor for use on other kidney diseases, such as autosomal dominant polycystic kidney disease (PKRAD).

What: Nabla, an AI assistant for doctors and healthcare professionals

Why: To allow healthcare professionals with their admin by generating written clinical notes and reports, across multiple medical sectors in seconds

Funding: €22 million

Who: Co-Founders Martin Raison, Delphine Groll, Alexandre Lebrun

Investors: Cathay Innovation, Zebox Ventures

What's next: The raise will enable Nabla to boost expansion across U.S. healthcare systems and continue transforming the way providers deliver care.

What: Hiboo, a construction tech SaaS platform.

Why: To help manufacturers optimize the use and energy efficiency of their site machinery/industrial equipment by making operations more efficient and environmentally responsible.

Funding: €9.3 million

Who:  Co-Founders Clément Bénard & Marie de Raismes - Baron

Investors: Emerald Technology Ventures, Isai Build Venture, Future Industry Ventures, Ring Capital, Citizen Capital

What's next: The new funding will enable Hiboo to accelerate the development of new products, strengthen its teams, and fuel its international expansion, notably in Europe and the United States.

What: Womed, a biotech specializing in innovative and safe treatments.

Why: To free women from complex uterine pathologies such as infertility, uterine bleeding, and endometriosis.

Funding: €6 million

Who:  Co-Founders, Gonzague Issenmann, Dr. Stéphanie Huberlant, Prof. Xavier Garric``

Investors: Irdi & Family-offices

What's next: Womed will use the funds to launch the commercialization of its intrauterine device against infertility.